<DOC>
	<DOCNO>NCT02881138</DOCNO>
	<brief_summary>A tolerance , safety pharmacokinetic ascend dose Phase I Study RC48-ADC Administered Intravenously Subjects With HER2-Positive malignant Advanced Malignant solid Tumors .</brief_summary>
	<brief_title>Study RC48-ADC Patients With HER2-Positive Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed informed consent form ; Aged 1865 year ; ECOG physical condition 0 1 ; Life expectancy great 12 week ; Patients locally advance metastatic malignant solid tumor diagnose pathology refractory standard care therapy , standard care therapy available histology standard care therapy , standard care therapy available ; Documented Human epidermal growth factor receptor 2 ( HER2 ) positive measure either immunohistochemistry ( IHC 2+ fluorescence situ hybridization ( FISH ) immunohistochemistry ( score , 3+ ) ; Patients measurable appreciable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) ; Adequate organ function define follow criterion : absolute neutrophil count ( ANC ) &gt; = 1.5 x 10 ( 9 ) /L ; platelet &gt; =70*10 ( 9 ) /L ; Total serum bilirubin &lt; =1.5*ULN ; serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) &lt; =3.0*upper limit normal ( ULN ) , AST ALT &lt; =5*ULN liver function abnormality due underlying malignancy ; normal serum creatinine ; international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) must less equal 1.5 time upper limit normal range ( ULN ) ; Women childbearing potential men must agree use adequate contraception ( e.g. , condom , implant , injectables , combine oral contraceptive , intrauterine device [ IUDs ] , complete sexual abstinence , sterilize partner ) prior study entry period therapy 30 day last dose study drug ; Left ventricular ejection fraction ( LVEF ) &gt; = 50 % assessed echocardiogram . Current pregnancy lactation ; Major surgery within 4 week first dose study drug fully recover receive palliative radiation therapy bone metastasis administer &lt; = 2 week prior first study treatment ; Unresolved toxicities prior anticancer therapy , define resolved Common Terminology Criteria Adverse Event ( CTCAE , version 4 ) , grade less equal to1 , level dictate inclusion/exclusion criterion exception alopecia ; Priortreatment clinical research anticancer drug within 28 day study drug treatment ; Participated clinical drug study within 4 week ; receive antineoplaston therapy include chemotherapy radiotherapy , hormonal cancer therapy , biological therapy immunotherapy within 4 week start study treatment , except follow treatment : aiming treatment prostate cancer gonadotropin release hormone ( GnRH ) antagonist ; Hormone replacement therapy ; know hypersensitivity delay hypersensitivity component RC48ADC similar drug ; active infection clinical significance accord researcher 's judgment ; Known history immune deficiency , include HIVpositive know acquire congenital immunodeficiency , organ transplantation ; Currently active clinically significant cardiovascular disease uncontrolled arrhythmia , congestive heart failure , great equal Class 2 congestive heart failure define New York Heart Association Functional Classification , history myocardial infarction unstable angina , acute coronary syndrome within 6 month prior enrollment study ; Unwilling unable participate require study evaluation procedure ; time interval last chemotherapy HER2 target therapy first trial 21 day ; Patients receive systemic steroid therapy long time ( Patients receive systemic steroid therapy short time stop drug 2 week could enrol ) ; Serious complication diabetes , interstitial pneumonia , pulmonary fibrosis , hypertension Acute lung disease ; Patients use trastuzumab 60 day experiment ; Uncontrolled primary metastatic tumor brain ; Current peripheral neuropathy Grade â‰¥ 2 ; History nerve psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>